Paul has stated for as long as I can remember that he wants to progress this as far as he can before arriving at a pharmaceutical JV.
If he pulls this off, without another cap raise to his weary, war-torn retail investors and arrives at a healthy revenue % due to the exceptional molecule, drug effect size and total addressable market, he will be back on my Christmas card list.
We are at the mercy of the FDA now. SW, Matt, Paul, Donna and KOL’s, bring this one home to Poppa.
One senses a few more hurdles to overcome to arrive at a Stage 2 of Phase 3 that ticks all the boxes.
Revised n
Optimal Dose
DMOAD label
Paul has stated for as long as I can remember that he wants to...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 29.5¢ | $34.55K | 115.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 40478 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |